CAMBRIDGE, England & BOSTON, March 30, 2026--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to ...
Nuclera, announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). Building on the eProtein Discovery™ membrane protein workflow capabilities ...
The discovery of G protein-coupled receptor (GPCR) heteromers has revealed a new level of complexity in their functional characteristics. This review explores a variety of methodologies and live cell ...
GPCRs (G-protein-coupled receptors) represent the largest family of membrane receptors currently targeted by approved drugs. It is estimated that approximately 700 approved drugs target GPCRs ...
Versatility, thy name is G protein–coupled receptor (GPCR). Besides responding to diverse extracellular stimuli, GPCRs initiate diverse signaling reactions. Indeed, most GPCRs are multivalent. That is ...
Innovative approach expands drug discovery possibilities for targets beyond the reach of conventional methodTo be presented ...
Enables expression of active GPCRs in 48 hours Panel supports screening to scale-up on eProtein Discovery Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today ...
Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results